Search research articles
Contact Us
Filters
Showing results (91-100 of 176) with videos related to
Page
of 18
Sort By:
Cell Death Discovery
|
June 19, 2024
Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma
Adrien Krug, Rana Mhaidly, Marie Tosolini, et al.
Blood Advances
|
April 17, 2023
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, et al.
Blood Advances
|
January 28, 2025
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study
Xavier Phina-Ziebin, Emmanuel Bachy, François-Xavier Gros, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Scientific Reports
|
November 5, 2020
Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
Catherine Belin, Perrine Devic, Xavier Ayrignac, et al.
Blood Advances
|
April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
Estelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Bone Marrow Transplantation
|
April 17, 2021
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT
Toby A Eyre, Sophie Caillard, Herve Finel, et al.
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Hemasphere
|
December 10, 2025
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Jean Galtier, Pierre Sesques, Vivien Dupont, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 176) with videos related to
Sort By:
Page
of 18
Cell Death Discovery
|
June 19, 2024
Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma
Adrien Krug, Rana Mhaidly, Marie Tosolini, et al.
Blood Advances
|
April 17, 2023
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, et al.
Blood Advances
|
January 28, 2025
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study
Xavier Phina-Ziebin, Emmanuel Bachy, François-Xavier Gros, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Scientific Reports
|
November 5, 2020
Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
Catherine Belin, Perrine Devic, Xavier Ayrignac, et al.
Blood Advances
|
April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
Estelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Bone Marrow Transplantation
|
April 17, 2021
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT
Toby A Eyre, Sophie Caillard, Herve Finel, et al.
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Hemasphere
|
December 10, 2025
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Jean Galtier, Pierre Sesques, Vivien Dupont, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Page
of 18